Sign up to save your podcasts
Or
Share BioNTech's Richardson on Drug Pipeline
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BioNTech's Richardson on Drug Pipeline
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.
See omnystudio.com/listener for privacy information.
View all episodes
By Bloomberg
5
22 ratings
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.
See omnystudio.com/listener for privacy information.
More shows like Vanguards of Health Care by Bloomberg Intelligence
View all
Bloomberg Surveillance
1,199 Listeners
Masters in Business
2,174 Listeners
Odd Lots
1,784 Listeners
FYI - For Your Innovation
394 Listeners
The Long Run with Luke Timmerman
122 Listeners
GZERO World with Ian Bremmer
771 Listeners
Value Hive Podcast
91 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,189 Listeners
Raising Health
147 Listeners
The Business Brew
246 Listeners
The Ezra Klein Show
15,237 Listeners
Business Breakdowns
351 Listeners
Bloomberg Talks
17 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
461 Listeners
Money Stuff: The Podcast
371 Listeners